Bisphosphonates can block the deterioration in implant fixation after withdrawal of intermittent doses of parathyroid hormone.

We have examined the deterioration of implant fixation after withdrawal of parathyroid hormone (PTH) in rats. First, the pull-out force for stainless-steel screws in the proximal tibia was measured at different times after withdrawal. The stimulatory effect of PTH on fixation was lost after 16 days. We then studied whether bisphosphonates could block this withdrawal effect. Mechanical and histomorphometric measurements were conducted for five weeks after implantation. Subcutaneous injections were given daily. Specimens treated with either PTH or saline during the first two weeks showed no difference in the mechanical or histological results (pull-out force 76 N vs 81 N; bone volume density 19% vs 20%). Treatment with PTH for two weeks followed by pamidronate almost doubled the pull-out force (152 N; p < 0.001) and the bone volume density (37%; ANOVA, p < 0.001). Pamidronate alone did not have this effect (89 N and 25%, respectively). Thus, the deterioration can be blocked by bisphosphonates. The clinical implications are discussed.

[1]  R. Turner,et al.  Intermittent parathyroid hormone (PTH) treatment and age‐dependent effects on rat cancellous bone and mineral metabolism , 2007, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[2]  P. Aspenberg,et al.  Stimulation of implant fixation by parathyroid hormone (1–34)–A histomorphometric comparison of PMMA cement and stainless steel , 2005, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[3]  T. Einhorn,et al.  Bisphosphonates in orthopaedic surgery. , 2005, The Journal of bone and joint surgery. American volume.

[4]  R. Weinstein,et al.  IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice. , 2005, American journal of physiology. Endocrinology and metabolism.

[5]  L. Gelbert,et al.  Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: An analysis by DNA microarray , 2005, Journal of cellular biochemistry.

[6]  P. Aspenberg,et al.  Systemic and local ibandronate enhance screw fixation , 2004, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[7]  N. Lane,et al.  Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). , 2004, The Journal of clinical endocrinology and metabolism.

[8]  Kwan Tat Steeve,et al.  IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. , 2004 .

[9]  P. Aspenberg,et al.  PerspectiveParathyroid hormone—a drug for orthopedic surgery? , 2004, Acta orthopaedica Scandinavica.

[10]  P. Roberson,et al.  Proteasomal Degradation of Runx2 Shortens Parathyroid Hormone-induced Anti-apoptotic Signaling in Osteoblasts , 2003, Journal of Biological Chemistry.

[11]  B. L. Riggs,et al.  Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone , 2003, Journal of cellular biochemistry.

[12]  S. Khosla,et al.  Minireview: the OPG/RANKL/RANK system. , 2001, Endocrinology.

[13]  P. Aspenberg,et al.  Parathyroid hormone (1–34) increases attachment of PMMA cement to bone , 2001, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association.

[14]  P. Aspenberg,et al.  Early Effect of Parathyroid Hormone (1–34) on Implant Fixation , 2001, Clinical orthopaedics and related research.

[15]  P. Aspenberg,et al.  Implant fixation enhanced by intermittent treatment with parathyroid hormone. , 2001, The Journal of bone and joint surgery. British volume.

[16]  C. Rosen,et al.  Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. , 2000, The Journal of clinical endocrinology and metabolism.

[17]  P. Aspenberg,et al.  Strong effect of PTH (1-34) on regenerating bone: A time sequence study in rats , 2000, Acta orthopaedica Scandinavica.

[18]  P. Roberson,et al.  Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. , 1999, The Journal of clinical investigation.

[19]  J. Lorenzo,et al.  Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. , 1999 .

[20]  H. Oxlund,et al.  Intermittent Parathyroid Hormone (1–34) Treatment Increases Callus Formation and Mechanical Strength of Healing Rat Fractures , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  P. Aspenberg,et al.  Migration, particles, and fluid pressure. A discussion of causes of prosthetic loosening , 1998 .

[22]  L. Stitt,et al.  A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. , 1997, The Journal of clinical endocrinology and metabolism.

[23]  F. Melsen,et al.  Parathyroid hormone (1-34) increases vertebral bone mass, compressive strength, and quality in old rats. , 1995, Bone.

[24]  R. Turner,et al.  Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. , 1995, Endocrinology.

[25]  Truls Østbye,et al.  An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. , 1993, The Journal of clinical investigation.

[26]  S. Kwan Tat,et al.  IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. , 2004, Cytokine & growth factor reviews.

[27]  P. Aspenberg,et al.  Parathyroid hormone (1-34) increases the density of rat cancellous bone in a bone chamber. A dose-response study. , 2000, The Journal of bone and joint surgery. British volume.

[28]  P. Aspenberg,et al.  Parathyroid hormone (1-34) increases the density of rat cancellous bone in a bone chamber , 2000 .

[29]  J. Hock,et al.  Loss of the anabolic effect of parathyroid hormone on bone after discontinuation of hormone in rats. , 1989, Bone.